Vertex Pharmaceuticals (VRTX) Q4 2025 (USD): Adj. EPS 5.03 (exp. 5.11), Revenue 3.19bln (exp. 3.18bln); FY26 revenue view 12.95-13.1bln (exp. 13.02bln)
Importance
Level 1
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#VERTEX PHARMACEUTICALS INC#VRTX.US#FOREX#EQUITIES#METALS#ASIAN SESSION#US SESSION#BIOTECHNOLOGY#METALS & MINING#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#VRTX#DXY#US EQUITIES